Elanco Animal Health (NYSE:ELAN) Insider Acquires $95,985.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Rajeev Modi acquired 4,500 shares of the company’s stock in a transaction dated Thursday, December 11th. The shares were acquired at an average cost of $21.33 per share, with a total value of $95,985.00. Following the completion of the purchase, the insider owned 123,082 shares in the company, valued at approximately $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Elanco Animal Health Price Performance

ELAN stock traded up $0.43 on Monday, reaching $21.72. The company had a trading volume of 5,970,920 shares, compared to its average volume of 5,860,102. The company’s fifty day moving average is $21.73 and its 200 day moving average is $18.10. The company has a market cap of $10.79 billion, a P/E ratio of 361.98, a PEG ratio of 2.89 and a beta of 1.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $23.70.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business’s revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ELAN. Hsbc Holdings PLC lifted its stake in shares of Elanco Animal Health by 434.2% during the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock worth $1,801,000 after purchasing an additional 102,686 shares in the last quarter. Norges Bank purchased a new stake in shares of Elanco Animal Health during the 2nd quarter valued at about $12,502,000. Comerica Bank lifted its position in Elanco Animal Health by 46.4% during the 1st quarter. Comerica Bank now owns 49,680 shares of the company’s stock worth $522,000 after acquiring an additional 15,754 shares in the last quarter. Equitable Trust Co. boosted its holdings in Elanco Animal Health by 65.5% in the 2nd quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock worth $3,543,000 after acquiring an additional 98,172 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in Elanco Animal Health by 14.0% in the first quarter. PNC Financial Services Group Inc. now owns 13,404 shares of the company’s stock valued at $141,000 after acquiring an additional 1,641 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 8th. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Barclays started coverage on Elanco Animal Health in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Zacks Research downgraded Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.78.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.